Strugnell et al., Abstract to “1 alpha, 24(S)-dihydroxyvitamin D2: a biologically active product of 1 alpha-hydroxyvitamin D2 made in the human hepatoma, Hep3B”, from Biochemical Journal, 310 (Pt 1), pp. 233-241, Aug. 15, 1995.* |
Horst et al., . . . Biochem., vol. 32, No. 11, pp. 2060-2063, 1986.* |
Miller et al., “The Human Prostatic Carcinoma Cell Line LNCaP Expresses Biologically Active, Specific Receptors for 1α,25-Dihydroxyvitamin D31 ,” 52 Cancer Res. (1992) 515-520. |
Skowronski et al., “Actions Of Vitamin D3 Analogs on Human Prostate Cancer Cell Lines: Comparison with 1,25-Dihydroxyvitamin D3 ” 136 Endocrinology (1995) 20-26. |
Skowronski et al., “Vitamin D and Prostrate Cancer: 1,25 Dihydroxyvitamin D3 Receptors and Actions in Human Prostate Cancer Cell Lines,” 132 Endocrinology (1993) 1952-1960. |
R. Belsey et al., Rapid Communications, pp. 554-557 (1971). |
E. G. Bligh, Canadian Journal of Biochemistry and Physiology, vol. 37, pp. 911-917 (1959). |
Harrison's Principles of Internal Medicine: Part Seven, “Disorders of Bone and Mineral Metabolism: Chap. 35,” in E. Braunwald et al., Calcium, Phosphorus and Bone Metabolism: Calcium Regulating Hormones, McGraw-Hill, New York, pp. 1860-1865, 1992. |
H. F. DuLuca et al., Prog. Clin. Biol Res., vol. 259, pp. 41-55 (1988). |
M.F. Holick et al., J. Biol. Chem., vol. 248, pp. 6691-6696 (1973). |
B. W. Hollis, Clin. Chem., vol. 32, No. 11, pp. 2060-2063 (1986). |
R. L. Horst et al., Biochem., vol. 29, pp. 578-582 (1990). |
S. Ishizuka et al., Steroids, vol. 37, No. 1, pp. 33-42 (1981). |
S. Ishizuka et al., Steroids, vol. 39, No. 1, pp. 53-62 (1982). |
G. Jones, Clin. Chem., vol. 24, No. 2. pp. 287-298 (1978). |
G. Jones et al., Biochemistry, vol. 18, No. 6, pp. 1094-1101 (1979). |
G. Jones et al., Archives of Biochemistry and Biophysics, vol. 202, No. 2, pp. 450-457 (1980). |
H. E. Paaren et al, J. Org. Chem., vol. 45. pp. 3253-3258 (1980). |
J. G. Rheinwald et al., Cell, vol. 6. pp. 331-343 (1975). |
H. L. Shieh et al., Chem-Biol. Interact, vol. 81, pp. 35-55 (1992). |
S. Strugnell et al., Biochemical Pharmacology, vol. 40, pp. 333-341 (1990). |
S. Tam et al., Journal of Lipid Research, vol. 29, pp. 1637-1642 (1988). |
N. J. Koszewski et al., “Use of Fourier Transform H NMR in the Identification of Vitamin D2 Metabolites”, Analytical Biochemistry, vol. 162 (1987). |
G. W. Engstrom et al. “Metabolism of Vitamin D2 in Pig Liver Homogenates: Evidence for a Free Radical Reaction”, Archives of Biochemistry and Biophysics, vol. 270, No. 2, pp. 432-440 (1989). |
G. S. Reddy et al., “24,25,28-Trihydroxyvitamin D2 and 24,25,26-Trihydroxyvitamin D2: Novel Metabolites of Vitamin D2”, vol. 29, No. 4, pp. 943-949 (1990). |
Calcium Regulation and Bone Metabolism Basic and Clinical Aspects, vol. 9 in R. L. Horst et al., Quantitation and Biological Evaluation of the C-24 Hydroxylation Pathway of Vitamin D2 , Excerpta Medica, Amsterdam-New York-Oxford, p. 598, 1987. |
Beer, et al., “A Phase I Trial of Pulse Calcitriol in Patients with Refractory Malignancies,” Cancer, vol. 91, No. 12 (Jun. 15, 2001) 2431-2439. |
Beer, et al., “Weekly High-Dose Calcitriol and Docetaxel in Advanced Prostate Cancer,” Seminars in Oncology, vol. 28, No. 4., Suppl 15 (Aug. 2001) 49-55. |
Kim, Joonggon, “Synthesis in the Vitamin D Series. A Novel Route to Ring A Synthon and Vitamin D Analogs (Hydroxyvitamin D),” Thesis submitted at University of Illinois Chicago, Publication No. AAT 9335131, 1993. |